Catalyst Pharmaceuticals Partners, Inc.
Mid Cap · Healthcare · Biotechnology
$31.49+$0.00 (+0.00%)
Catalyst Pharmaceuticals Partners, Inc.
Mid Cap · Healthcare · Biotechnology
$31.49+$0.00 (+0.00%)
Stock analysis
Get the AI take on CPRX
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$19.05
High$32.56
Today $31.49
Overall score
71/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Current price
$31.49
Lowest
$31.5
Median target
$31.5
Highest
$32
LowHigh
Operating Record
Revenue
What's working
- Cash exceeds debt by $753.2M, leaving a net cash buffer, a good sign.
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
What the market charges
Forward P/E
Favorable · 29% below avg
15.69x
Price / sales
Reasonable · Priced reasonably against its revenue
6.46x
Price / FCF
Strong · Priced well within what its cash flow supports
18.52x
EV / EBITDA
Strong · Operating earnings comfortably support this price
10.14x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
78.8%
ROE
Favorable · 24.5% - strong capital efficiency
24.5%
Debt / equity
Favorable · 0.00 - strong leverage
0.00x
Current ratio
Strong · Comfortable room to cover bills due within a year
7.10x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $3.84B | 18.1 | +11.7% | 71 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |